Abstract
Plasma-derived HB vaccine which is inacivated HBsAg purifeied from plasma of HBV carriers, has been aplied the clinical use in Japan, Plasma-derived vaccine has the disadvantage as follows: 1) It is limmited to obtain the raw materials which come from plasma of HBV carriers. 2) This vaccine can not be completely indeniable the comtamination of unknown viruses. 3) It is necessary chimpanzees for its safty test.Yeast- and cell-derived recombinant HB vaccines are now studying, as the second generation vaccine.Three dose injection (0, 1, 6 month) of plasma-derived HB vaccine (one dose: 20 mcg in adult, 10 mcg in infant) is needed for the prevention of HBV infection. When exposed HBV, administration of immunoglobulin containng high titier anti-HBs (HBIG) and HB vaccine simultaneously is necessary. For the control of HBV carrier, the prevention of HBV infection against babies from HBeAg positive mothers started the beginning of this year in Japan.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
